$EXPO

EXPONENT INC

1
0
0
$13K
—
Souri Shukri Jeries
0%
See all $EXPO insider activity →
Low

Analysts Offer Insights on NA Companies: Exponent (EXPO) and Generac Holdings (GNRC)

Analysts from William Blair and Stifel Nicolaus maintained Buy ratings on Exponent (EXPO) and Generac Holdings (GNRC) respectively. EXPO has a Strong Buy consensus and $84.00 price target, while GNRC has a Moderate Buy consensus and $295.79 price target, reflecting a 42.3% upside. Both stocks closed at $64.53 and $212.22 last Tuesday.

Expo Engineering and Projects Ltd receives order worth Rs. 18.51 crore

Expo Engineering and Projects Ltd said it received an order dated Aug 10, 2026 from Indian Oil Corp Ltd (Pipelines Division, Western Region Pipelines, Rajkot) worth Rs. 18.51 crore including taxes. The work covers Maintenance and Inspection of crude oil storage tank VT-08 at WRPL, Viramgam. The BSE stock last traded at Rs. 82.29.

EXPO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning EXPO (EXPONENT INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent EXPO coverage spans financial news, insider activity and earnings.

In the last 30 days, EXPO insiders filed 1 SEC Form 4 transaction — 1 purchase ($13K) and no sales. The most active reporter was Souri Shukri Jeries, Group Vice President, with 1 filing.

What's driving EXPO

AlphAI scores every news story that mentions EXPO with an AI model for sentiment and relevance, and aggregates insider trades from EXPONENT INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $EXPO

Score
$EXPOMedAI 8/10

Exponent (EXPO) Q2 2026 Earnings Call Transcript

Exponent, Inc. (EXPO) reported Q2 2026 net revenues of $148.9 million, up 12% from $132.9 million a year earlier, and net income of $29.4 million, up 11%. Diluted EPS was $0.60. Management raised FY 2026 revenue guidance to 9% to 10% growth and EBITDA margin to 27.8% to 28.1%, and authorized an additional $50 million for share repurchases.

$EXPOMedAI 8/10

Exponent Q2 Earnings Call Highlights

Exponent (NASDAQ:EXPO) reported Q2 EBITDA up 16% to $42.7 million, with EBITDA margin at 28.7% of net revenue versus 27.8% a year earlier. Billable hours rose 8% to about 390,000 and utilization increased to 74%. The company repurchased $67.4 million of stock and paid $14.8 million in dividends. It raised 2026 outlook for net revenue growth of 9% to 10%.

$EXPOLow

EXPONENT INC (EXPO): Submission of Matters to a Vote of Security Holders

EXPONENT INC (EXPO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000851520 0000851520 2026-06-04 2026-06-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

$EXPOMed

UBS Group Cuts Exponent (NASDAQ:EXPO) Price Target to $75.00

UBS Group has reduced its price target for Exponent (NASDAQ:EXPO) from $85.00 to $75.00, maintaining a "neutral" rating on the stock. This adjustment comes despite Exponent reporting better-than-expected Q1 earnings with EPS of $0.59 and revenue of $166.3 million, and the company increasing its quarterly dividend and share buyback authorization. Insiders have been net sellers, and the stock is currently trading down, with a P/E ratio around 31.

Earnings call transcript: Exponent Q1 2026 sees stock rise post-earnings

Exponent Inc. reported Q1 2026 earnings, with EPS of $0.57 exceeding forecasts and revenue of $144.47 million meeting expectations. The company's stock rose by 1.07% in aftermarket trading, reflecting strong performance driven by AI integration in consumer electronics and increased demand from energy and utility sectors. Exponent's CEO highlighted a strategic focus on innovation, while new President John Pye and CFO Eric Anderson were introduced, signaling a leadership evolution to capitalize on developing market trends.

$EXPOMed

JPMorgan Chase & Co. Sells 157,457 Shares of Exponent, Inc. $EXPO

JPMorgan Chase & Co. reduced its stake in Exponent, Inc. (NASDAQ:EXPO) by 24.7% in the third quarter, selling over 157,000 shares, though still holding 480,624 shares valued at $33.39 million. While other institutional investors made significant purchases, company insiders, including the CEO and a VP, sold a combined 9,583 shares. Exponent, which analysts rate a "Moderate Buy" with a $92.50 average target, recently beat earnings estimates and increased its quarterly dividend.

Related tickers